Santen Pharmaceutical (OTCMKTS:SNPHY) Trading Up 6.6% – Time to Buy?

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY)’s stock price was up 6.6% during trading on Wednesday . The company traded as high as $11.9620 and last traded at $11.9620. Approximately 521 shares traded hands during trading, a decline of 96% from the average daily volume of 13,901 shares. The stock had previously closed at $11.22.

Analysts Set New Price Targets

Separately, Zacks Research upgraded Santen Pharmaceutical to a “hold” rating in a report on Monday, April 13th. One analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the company currently has an average rating of “Hold”.

Santen Pharmaceutical Stock Up 6.6%

The firm has a fifty day moving average price of $11.27 and a 200-day moving average price of $10.88. The firm has a market cap of $3.86 billion and a price-to-earnings ratio of 0.10.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.